<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418571</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0171-C203</org_study_id>
    <nct_id>NCT03418571</nct_id>
  </id_info>
  <brief_title>Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  to evaluate the safety, tolerability, and systemic pharmacokinetics (PK) of different
           doses of inhaled ALX-0171 in Japanese infants and young children hospitalized for
           respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI).

        -  to evaluate the antiviral effect, clinical activity, immunogenicity, and
           pharmacodynamics (PD) of different doses of inhaled ALX-0171 in Japanese infants and
           young children hospitalized for RSV LRTI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by the incidence of treatment-emergent (serious) adverse events</measure>
    <time_frame>From time of first dose to 28 days after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics as measured by the concentration of ALX-0171 in serum</measure>
    <time_frame>Day 2 - Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for viral load to drop below assay quantification limit (BQL)</measure>
    <time_frame>From day of first dose to 14 days after first dose</time_frame>
    <description>Time needed for the viral load to drop below the assay quantification limit (time-to-BQL) in nasal swab specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Severity Score</measure>
    <time_frame>From day of first dose to 14 days after first dose</time_frame>
    <description>Evolution over time in Global Severity Score. The Global Severity Score is the sum of the scores of 7 individual items, i.e., feeding, medical interventions, respiratory distress, respiratory rate, apnea, general appearance and body temperature. All items are scored from 0 to 3, except for body temperature that is scored from 0 to 2. The total maximum score is 20 points. Higher score indicates more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response</measure>
    <time_frame>From day of first dose to 28 days after first dose</time_frame>
    <description>Evaluation of the clinical response of the subjects as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by the concentration of anti-ALX 0171 antibodies in serum</measure>
    <time_frame>From day of first dose to 28 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Respiratory Syncytial Virus Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 Dose 1</intervention_name>
    <description>Inhalation of ALX-0171 Dose 1 once daily for 3 consecutive days</description>
    <arm_group_label>ALX-0171 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 Dose 2</intervention_name>
    <description>Inhalation of ALX-0171 Dose 2 once daily for 3 consecutive days</description>
    <arm_group_label>ALX-0171 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 Dose 3</intervention_name>
    <description>Inhalation of ALX-0171 Dose 3 once daily for 3 consecutive days</description>
    <arm_group_label>ALX-0171 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX0171 Dose 4</intervention_name>
    <description>Inhalation of ALX-0171 Dose 4 once daily for 3 consecutive days</description>
    <arm_group_label>ALX-0171 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhalation of Placebo once daily for 3 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is of Japanese descent, i.e., born in Japan to Japanese parents and has
             Japanese maternal and paternal grandparents.

          -  Subject is otherwise healthy, but is hospitalized for and clinically diagnosed with
             RSV LRTI

          -  Subject has a positive RSV diagnostic test.

          -  Symptoms likely related to RSV infection have appeared within 4 days of screening and
             are not yet improving

        Others as defined in the protocol

        Exclusion Criteria:

          -  Subject is known to have significant comorbidities

          -  Subject is known to be immunocompromised

          -  Subject has or is suspected to have an active, clinically relevant concurrent
             infection

          -  Subject received invasive mechanical ventilation or non-invasive respiratory support
             (i.e., continuous or bilevel positive airway pressure) in the 4 weeks prior to
             screening.

        Others as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ablynx Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ablynx NV Belgium</last_name>
    <phone>+32 9 262 00 00</phone>
    <email>clinicaltrials@ablynx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Aoi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Asahikawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Fuchu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Fukuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Funabashi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Isesaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Koga</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kurume-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Meguro-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Minami-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Nagano-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Saitama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Shimotsuke-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Toyohira</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Ueda</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Wako</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Yachiyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Yokosuka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Yokosuka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ōmura</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

